Ischemic stroke prevention

被引:2
作者
Seemant Chaturvedi
Susan Hickenbottom
Steven R. Levine
机构
[1] Wayne State University School of Medicine,
[2] University of Michigan Medical Center,undefined
关键词
Warfarin; Clopidogrel; Dipyridamole; Ticlopidine; Stroke Prevention;
D O I
10.1007/s11940-999-0011-y
中图分类号
学科分类号
摘要
More than 700,000 strokes occur annually in the United States—one every 40 to 50 seconds. Although stroke is one of the nation’s most expensive diseases to treat, costing $41 billion per year, most strokes (perhaps as many as two thirds) are preventable. Twenty percent of the United States population will have 80% of all strokes; this estimate is based on five established, major risk factors for stroke: hypertension, diabetes mellitus, cigarette smoking, hyperlipidemia, and heart disease. Therefore, stroke is not random but is generally predictable. It is an ideal target for effective prevention strategies that are simple and inexpensive. Ischemic stroke prevention has been shown to be effective in several scenarios: primary prevention, prevention after a transient ischemic attack (TIA), and secondary prevention. Dietary, lifestyle, and risk factor modification; use of aspirin, ticlopidine, clopidogrel, and warfarin; and carotid endarterectomy all have a role in stroke prevention in selected persons. Emerging therapies include the use of vitamins, cerebral arterial angioplasty, and stenting. Annual risk assessment, screening, and intervention should be part of a concerted national effort to reduce the incidence of the third leading cause of death and the number one cause of adult disability in the United States.
引用
收藏
页码:113 / 125
页数:12
相关论文
共 50 条
  • [41] Primary and Secondary Prevention of Ischemic Stroke and Cerebral Hemorrhage
    Diener, Hans-Christoph
    Hankey, Graeme J.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2020, 75 (15) : 1804 - 1818
  • [42] Antithrombotic Therapy in the Prevention of Stroke
    Bir, Shyamal
    Kelley, Roger E.
    BIOMEDICINES, 2021, 9 (12)
  • [43] Dual antiplatelet therapy for secondary stroke prevention in patients with acute ischemic stroke. CIERTO group recommendation
    Izcovich, Ariel
    Caruso, Diego
    Tisi Bana, Matias
    Bottaro, Federico
    Pollan, Javier
    Saavedra, Ezequiel
    Catalano, Hugo N.
    MEDICINA-BUENOS AIRES, 2019, 79 (04) : 315 - 321
  • [44] Antiplatelet Therapy in the Secondary Prevention of Non-cardioembolic Ischemic Stroke and Transient Ischemic Attack: A Mini-Review
    Valis, Martin
    Klimova, Blanka
    Novotny, Michal
    Herzig, Roman
    FRONTIERS IN NEUROLOGY, 2021, 12
  • [45] P2Y12 receptor inhibitors for secondary prevention of ischemic stroke
    Liu, Fang
    Tantry, Udaya S.
    Gurbel, Paul A.
    EXPERT OPINION ON PHARMACOTHERAPY, 2015, 16 (08) : 1149 - 1165
  • [46] Trends in the Use of Medications for Secondary Ischemic Stroke Prevention in Denmark, 2005-2021
    Skajaa, Nils
    Laugesen, Kristina
    Lauffenburger, Julie C.
    Schwamm, Lee H.
    Sorensen, Henrik T.
    Patorno, Elisabetta
    NEUROLOGY, 2024, 102 (09)
  • [47] Sex differences in antiplatelet response in ischemic stroke
    Meyer, Dawn M.
    Eastwood, Jo-Ann
    Compton, Margaret P.
    Gylys, Karen
    Zivin, Justin A.
    Ovbiagele, Bruce
    WOMENS HEALTH, 2011, 7 (04) : 465 - 474
  • [48] Antithrombotic secondary prevention after stroke
    Hans-Christoph Diener
    Peter Ringleb
    Current Treatment Options in Neurology, 2001, 3 (5) : 451 - 462
  • [49] Antiplatelet therapy for secondary stroke prevention
    Forbes, CD
    SCOTTISH MEDICAL JOURNAL, 1999, 44 (02) : 54 - 59
  • [50] Antiplatelet therapy for prevention of recurrent stroke
    Badruddin, Aamir
    Gorelick, Philip B.
    CURRENT TREATMENT OPTIONS IN NEUROLOGY, 2009, 11 (06) : 452 - 459